John Paulson Crispr Therapeutics Ag Transaction History

Paulson & Co. Inc.

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q3 2017 Nov 14, 2017	SELL	$16.75 - $20.66 $477,375 - $588,810	-28,500 Closed	0 $0
Q2 2017 Sep 20, 2017	BUY	N/A	28,500	28,500 $457,000

488

64.1M

1.64M

1.93M

Ticker CRSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,009,296
Market Cap $2.65B
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....

Get notified when there are updates to the investment portfolio of Paulson & Co. Inc., based on Form 13F filings with the SEC.

Stay updated on Paulson & Co. Inc. and John Paulson with notifications on news.